Johnson & Johnson 8-K
PositiveEarningsGuidance raised
Innovative Medicine and MedTech drove sales growth despite STELARA’s drag; FY2026 sales and adjusted EPS guidance raised.
Filed 2026-04-14 07:35 ET
- 2.02 Results of Operations
- 8.01 Other Events
- 9.01 Financial Statements and Exhibits
Summary
Q1 2026 results, raised FY2026 guidance and a dividend increase. Sales rose 9.9%, while GAAP net earnings fell 52.4%, largely reflecting a prior-year litigation-related gain; adjusted net earnings declined 1.4%. The Board raised the quarterly dividend 3.1%, marking 64 consecutive years of increases.
Key Figures
| Metric | Q1 2026 | Q1 2025 | Y/Y |
|---|---|---|---|
| Sales | $24.1B | $21.9B | 9.9% |
| Net earnings (GAAP) | $5.24B | $11.0B | -52.4% |
| Diluted EPS (GAAP) | $2.14 | $4.54 | -52.9% |
| Adjusted net earnings (non-GAAP) | $6.61B | $6.71B | -1.4% |
| Adjusted diluted EPS (non-GAAP) | $2.70 | $2.77 | -2.5% |
| Free cash flow (non-GAAP) | ≈$1.5B | $3.38B | — |
- Sales growth was driven by Innovative Medicine, up 7.4% operationally, and MedTech, up 4.6%; Innovative Medicine growth was partly offset by STELARA’s impact.
- Quarterly dividend: $1.34 per share, up from $1.30; indicated annual dividend $5.36 per share, up from $5.20. The next payment is 6/9/2026 to shareholders of record 5/26/2026.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Adjusted operational sales (non-GAAP) | FY2026 | 5.6%–6.6% Y/Y | 5.4%–6.4% Y/Y | Raised |
| Operational sales (non-GAAP) | FY2026 | $99.7B–$100.7B; 5.9%–6.9% Y/Y | $99.5B–$100.5B; 5.7%–6.7% Y/Y | Raised |
| Estimated reported sales | FY2026 | $100.3B–$101.3B; 6.5%–7.5% Y/Y | $100.0B–$101.0B; 6.2%–7.2% Y/Y | Raised |
| Adjusted operational diluted EPS (non-GAAP) | FY2026 | $11.30–$11.50; 4.7%–6.7% Y/Y | $11.28–$11.48; 4.5%–6.5% Y/Y | Raised |
| Adjusted diluted EPS (non-GAAP) | FY2026 | $11.45–$11.65; 6.1%–8.1% Y/Y | $11.43–$11.63; 5.9%–7.9% Y/Y | Raised |
Investor Takeaways
- Track quarterly sales and adjusted EPS against the raised FY2026 ranges; sustained growth in both segments would support the outlook.
- Johnson & Johnson plans an Enterprise Business Review on 12/8/2026, a future opportunity to assess its stated path to double-digit growth by decade-end.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3